BiomX Inc.

BiomX Inc. (ticker: PHGE) is a clinical-stage biopharmaceutical company that completed its business combination with Chardan Healthcare Acquisitions Corp, a blank-check company sponsored by Chardan Capital Markets, in October 2019. The company, which trades on the NYSE American exchange, develops phage-based therapeutics designed to target and destroy specific harmful bacteria, with programs focused on chronic rhinosinusitis, cystic fibrosis-related lung infections, and orthopedic device-related infections. Its most recent Form 10-Q, filed May 20, 2026, reflects continued clinical-stage operations as the company advances its pipeline. Visitors seeking comprehensive filing history, deal terms, and real-time pipeline updates for BiomX and the broader de-SPAC universe can sign up for full data access at SpacDesk.